Evidence map›Paper›PMID 36901951›Full record

ArticleInternational journal of molecular sciences2023

Response and Resistance to Trametinib in MAP2K1-Mutant Triple-Negative Melanoma.

Fanny Seraphine Krebs, Bianca Moura, Edoardo Missiaglia, Veronica Aedo-Lopez, Olivier Michielin, Petros Tsantoulis, Bettina Bisig, Mounir Trimech, Vincent Zoete, Krisztian Homicsko

Full text readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of molecular sciences, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Successful treatment ofFrontiers in medicine · 2024
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Fanny Seraphine KrebsComputer-Aided Molecular Engineering, Department of Oncology UNIL-CHUV, University of Lausanne, 1015 Lausanne, Switzerland.
Bianca MouraService of Medical Oncology, 1700 Fribourg, Switzerland.
Edoardo MissiagliaDepartment of Laboratory Medicine and Pathology, Institute of Pathology, Centre Hospitalier Universitaire Vaudois, Lausanne University, 1011 Lausanne, Switzerland.
Veronica Aedo-LopezMonash Medical Centre, Clayton, VIC 3168, Australia.
Olivier MichielinMolecular Modelling Group, SIB Swiss Institute of Bioinformatics, 1015 Lausanne, Switzerland.
Petros TsantoulisSwiss Cancer Center Leman, 1005 Lausanne, Switzerland.ORCID 0000-0003-3613-6682
Bettina BisigDepartment of Laboratory Medicine and Pathology, Institute of Pathology, Centre Hospitalier Universitaire Vaudois, Lausanne University, 1011 Lausanne, Switzerland.ORCID 0000-0002-6840-375X
Mounir TrimechDepartment of Laboratory Medicine and Pathology, Institute of Pathology, Centre Hospitalier Universitaire Vaudois, Lausanne University, 1011 Lausanne, Switzerland.
Vincent ZoeteComputer-Aided Molecular Engineering, Department of Oncology UNIL-CHUV, University of Lausanne, 1015 Lausanne, Switzerland.ORCID 0000-0002-2336-6537
Krisztian HomicskoLudwig Institute for Cancer Research, 1005 Lausanne, Switzerland.ORCID 0000-0003-0912-6198

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The development of targeted therapies for non-

Indexed as

MelanomaSkin NeoplasmsHumansMaleMAP Kinase Kinase 1Mitogen-Activated Protein Kinase KinasesMutationProtein Kinase InhibitorsProto-Oncogene Proteins B-rafPyridonesPyrimidinonesMAP2K1 protein, humanMAP Kinase Kinase 1Mitogen-Activated Protein Kinase KinasesProtein Kinase InhibitorsProto-Oncogene Proteins B-rafPyridonesPyrimidinonestrametinibcancerMAP2K1modellingmutationtriple-negative melanoma

Identifiers

PMID36901951
PMCPMC10003177

What OpenQuestion holds

Textfull text, public
LicenceCC BY
measurements read14
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.